• Explore /
  • Poster
  • / A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.

A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.

Abstract Poster

Authors

null

Eelke Gort

University Medical Center Utrecht, Utrecht, Netherlands

Eelke Gort , Melissa Lynne Johnson , Jimmy J. Hwang , Shubham Pant , Ulrich Dünzinger , Kathrin Riemann , Thomas Kitzing , Pasi A. Janne

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT04111458

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS3651)

DOI

10.1200/JCO.2020.38.15_suppl.TPS3651

Abstract #

TPS3651

Poster Bd #

381

Abstract Disclosures

Similar Posters

First Author: Iwona A. Lugowska

First Author: Anthony W. Tolcher

First Author: Anthony W. Tolcher

First Author: R. Donald Harvey